FDA’s Surprise Rejection: Lilly’s Eczema Breakthrough Stumbles Due to Manufacturing Hurdles

Eli Lilly, a pharmaceutical giant, received a surprising setback when the FDA rejected its promising antibody, lebrikizumab, intended for the treatment of moderate-to-severe atopic dermatitis. The reason? Manufacturing problems at a third-party contract manufacturing organization came under scrutiny during a multi-sponsor inspection, raising concerns about the production of lebrikizumab.

In a twist of fate, the FDA’s decision had nothing to do with the drug’s clinical efficacy, safety profile, or its proposed label. This setback, though unexpected, has not dampened Eli Lilly’s enthusiasm for lebrikizumab’s potential to provide relief for those suffering from eczema. Patrik Jonsson, the Executive Vice President of Lilly Immunology and Lilly USA, expressed the company’s unwavering confidence in the drug’s abilities.

Despite the initial rejection, Eli Lilly is determined to forge ahead. The company plans to collaborate closely with both the FDA and the third-party service provider to resolve the manufacturing issues swiftly. Their ultimate goal? To ensure that lebrikizumab becomes accessible to patients in need.

It’s important to note that this FDA decision doesn’t cast a shadow over Eli Lilly’s other pipeline or marketed products; the company remains steadfast in its commitment to innovation.

Lebrikizumab is positioned as a potential game-changer in the realm of moderate-to-severe atopic dermatitis. This biologic candidate targets the IL-13 cytokine, a key player in the immune system’s regulation, directly addressing the itching, skin thickening, and skin barrier dysfunction associated with the condition. Notably, lebrikizumab had previously earned the coveted FDA Fast Track designation.

Eli Lilly’s journey with lebrikizumab began when they submitted a Biologics License Application in the third quarter of 2022, supported by robust data from over 1,000 adult and adolescent patients across multiple studies, including ADvocate 1, AdDocate 2, and ADhere.

In a remarkable display of its potential, lebrikizumab, in combination with topical corticosteroids, outperformed a placebo, leading to clear or almost clear skin in patients with moderate-to-severe atopic dermatitis over a 16-week treatment period. Excitingly, additional data from ADvocate 1 and ADvocate 2 demonstrated that the majority of patients maintained skin clearance over a remarkable 52-week period.

Even more promising, subsequent data releases in September 2022 showcased the enduring benefits of lebrikizumab treatment, including sustained skin clearance, itch relief, and improvements in disease extent and severity.

Lebrikizumab is just one of Eli Lilly’s four investigational molecules slated for launch in 2023, as initially revealed during the 41st J.P. Morgan Healthcare Conference in January. Despite this setback, the company’s commitment to advancing innovative therapies remains unshaken.

The other candidates, including donanemab for Alzheimer’s disease and pirtobrutinib, now marketed as Jaypirca for relapsed or refractory mantle cell lymphoma, are still very much in the game.

In the dynamic world of pharmaceuticals, challenges may arise, but Eli Lilly’s determination to improve patients’ lives remains resolute, making the future an exciting and hopeful frontier.

Leave a Comment